{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T10:45:12Z","timestamp":1725705912395},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,1,5]],"date-time":"2004-01-05T00:00:00Z","timestamp":1073260800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study evaluated the overall efficacy and tolerability of quetiapine in the treatment of inpatients with acute mania who are intolerant to risperidone in combination with a mood stabilizer. Eighteen patients completed this 3\u2010week trial. The efficacy and tolerability was assessed upon admission, at baseline, and 1 and 3 weeks later. The Young mania rating scale (YMRS) and clinical global impression\u2010severity (CGI\u2010s) scores from the baseline to the endpoint, decreased by 39.8% and 40.0%, respectively. Fifteen (78.9%) and 18 (94.7%) patients exhibited at least a 50% improvement in the YMRS and CGI\u2010s scores by the end of the trial. Measurements taken through the Barnes akathisia rating scale (BARS), the Simpson\u2010Angus rating scale (SARS) and the drug attitude inventory shortened version\u201010 (DAI\u201010) also showed significant improvement.<\/jats:p><jats:p>This study suggests that quetiapine may hold promise as an alternative regimen that does not worsen the psychopathology, particularly for those vulnerable to the side effects of drugs, including atypical agents such as risperidone, in naturalistic treatment settings. Copyright \u00a9 2004 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hup.549","type":"journal-article","created":{"date-parts":[[2004,1,6]],"date-time":"2004-01-06T08:01:13Z","timestamp":1073376073000},"page":"47-51","source":"Crossref","is-referenced-by-count":8,"title":["Switching to quetiapine in patients with acute mania who were intolerant to risperidone"],"prefix":"10.1002","volume":"19","author":[{"given":"Chi\u2010Un","family":"Pae","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyong\u2010Uk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung\u2010Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang\u2010Uk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won\u2010Myong","family":"Bahk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo\u2010Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u2010Ho","family":"Paik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,1,5]]},"reference":[{"key":"e_1_2_1_2_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorder","author":"American Psychiatric Association","year":"1994"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1322-9"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2002.02229.x"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200210000-00011"},{"key":"e_1_2_1_7_1","unstructured":"GuyW.1976.ECDEUAssessment Manual for Psychopharmacology revised. DHEW Pub. No. (ADM) 76\u2013338. National Institute of Mental Health: Rockville MD."},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700050182"},{"key":"e_1_2_1_9_1","first-page":"423","article-title":"Risperidone in the treatment of affective illness and obsessive\u2010compulsive disorder","volume":"56","author":"Jacobsen FM","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(02)00293-2"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200103000-00005"},{"key":"e_1_2_1_12_1","first-page":"99","article-title":"Interactions between the cytochrome P450 system and the second\u2010generation antipsychotics","volume":"28","author":"Prior TI","year":"2003","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.7.1146"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0911"},{"key":"e_1_2_1_15_1","first-page":"55","article-title":"Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania","volume":"32","author":"Sajatovic M","year":"1996","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_16_1","first-page":"176","article-title":"Risperidone compared with both lithium and haloperidol in mania: a double\u2010blind randomized controlled trial","volume":"21","author":"Segal J","year":"1998","journal-title":"Clin Neuropharmacol"},{"issue":"20","key":"e_1_2_1_17_1","first-page":"22","article-title":"The Mini\u2010 International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM\u2010IV and ICD\u201010","volume":"59","author":"Sheehan DV","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(01)00481-5"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2002.01204.x"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200307000-00005"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.2.141"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.549","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T20:49:56Z","timestamp":1700254196000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1002\/hup.549"],"URL":"https:\/\/doi.org\/10.1002\/hup.549","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}